New Treatment Developments Applied to Elderly Patients

Metastatic prostate cancer remains a considerable therapeutic challenge; however, recent advances in clinical research have resulted in five new treatments with positive phase III trial results in the last 2 years. The immunotherapy sipuleucel-T, the cytotoxic cabazitaxel, the androgen biosynthesis inhibitor abiraterone acetate, the radioisotope Alpharadin, and the antiandrogen MDV3100 have all been shown to improve survival in randomized, phase III studies for patients with metastatic castration-resistant prostate cancer (CRPC). This chapter will discuss clinical trials in elderly patients with prostate cancer and review the clinical data regarding new developments as applied to the elderly population.